NEW YORK (GenomeWeb) – By combining whole-genome sequencing and artificial intelligence-based analysis, researchers have reported that they were able to quickly identify clinically actionable mutations within a brain tumor sample.

Researchers from the New York Genome Center, Rockefeller University, and IBM analyzed a glioblastoma sample through panel testing as well as whole-genome sequencing. That sequencing data was then analyzed by a team of bioinformaticians and oncologists at the center as well as by IBM's Watson for Genomics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.